Drugs / Clenbuterol
Clenbuterol
also known as
Clenbuterol hcl · CLENBUTEROL HYDROCHLORIDE · Contraspasmin · CST-103 · NAB 365 · NAB 365 CL · NSC-758633 · Planipart · +3 more
Small molecule targets ADRB2, DUX4 via activation / inhibition
Trials 12
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06721299 | Jun 2025 → Feb 2028 expected | facioscapulohumeral muscular dystrophy | Jeffrey Statland | Recruiting | No outcome recorded |
| Phase 1 | NCT00585546 | Jul 2007 → Mar 2010 | dilated cardiomyopathy, heart failure | Francis D. Pagani | Terminated | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01942590 | Sep 2013 → Sep 2016 | glycogen storage disease due to acid maltase deficiency, late-onset | Dwight Koeberl, M.D., Ph.D. | Completed | No outcome recorded |
| Phase 26 trials · 2 met primary · 1 missed | ||||||
| Phase 2 | NCT06169046 | Apr 2024 → Jun 2027 expected | bulbospinal muscular atrophy | Gianni Soraru | Recruiting | No outcome recorded |
| Phase 2 | NCT04094948 | Jan 2023 → Jun 2025 | glycogen storage disease due to acid maltase deficiency, late-onset | Duke University | Withdrawn | No outcome recorded Stop: Business |
| Phase 2 | NCT04921306 | Aug 2022 → Mar 2024 | type 2 diabetes mellitus | Maastricht University | Completed | Missed primary |
| Phase 2 | NCT04739423 | Jun 2021 → Jul 2022 | Lewy body dementia, Parkinson disease, REM sleep behavior disorder | CuraSen Therapeutics, Inc. | Completed | Met primary |
| Phase 2 | NCT04245709 | Feb 2020 → Mar 2021 | amyotrophic lateral sclerosis | Dwight Koeberl, M.D., Ph.D. | Completed | No outcome recorded |
| Phase 2 | NCT03800290 | Jun 2019 → Apr 2021 | — | Maastricht University | Completed | Met primary |
| Phase not applicable3 trials | ||||||
| — | NCT05692856 | Feb 2023 → Dec 2024 | — | Morten Hostrup, PhD | Unknown | No outcome recorded |
| — | NCT03860870 | Mar 2019 → Dec 2022 | — | University of Copenhagen | Completed | No outcome recorded |
| — | NCT02557581 | Jul 2015 → Jun 2017 | — | University of Copenhagen | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2023-03-30 | CuraSen Therapeutics, Inc. | Results CuraSen Therapeutics to Present Phase 2 Data Showing Rapid-Onset Cognition and Mood Benefit with CST-103/CST-107 (Clenbuterol/Nadolol) in Parkinson’s Disease at the Alzheimer’s Disease and Parkinson’s Disease (AD/PD’23) Conference curasen.com ↗
For the first time, we have been able to show improved outcomes in cognition and mood with adrenergic agonism in patients with neurodegenerative disease, by safely restoring a stimulus to the brain that is lost early in the pathologic process. |
All press releases naming this drug 3 releases
Evidence & citations 17 cited values
Every value below carries the sentence it was read from. 13 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Clenbuterol | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06169046 ↗ |
| Known as | Clenbuterol hcl | ChEMBL registry synonym — accepted as the source's own label CHEMBL49080 ↗ |
| Known as | CLENBUTEROL HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL49080 ↗ |
| Known as | Contraspasmin | ChEMBL registry synonym — accepted as the source's own label CHEMBL49080 ↗ |
| Known as | CST-103 | “clenbuterol (CST-103) and matching placebo orange capsules; nadolol (CST-107) and matching placebo white capsules” NCT04739423 ↗ |
| Known as | NAB 365 | ChEMBL registry synonym — accepted as the source's own label CHEMBL49080 ↗ |
| Known as | NAB 365 CL | ChEMBL registry synonym — accepted as the source's own label CHEMBL49080 ↗ |
| Known as | NSC-758633 | ChEMBL registry synonym — accepted as the source's own label CHEMBL49080 ↗ |
| Known as | Planipart | ChEMBL registry synonym — accepted as the source's own label CHEMBL49080 ↗ |
| Known as | Spiropent | ChEMBL registry synonym — accepted as the source's own label CHEMBL49080 ↗ |
| Known as | Spiropent mite | ChEMBL registry synonym — accepted as the source's own label CHEMBL49080 ↗ |
| Known as | Ventipulmin | ChEMBL registry synonym — accepted as the source's own label CHEMBL49080 ↗ |
| Action | Activate | “Beta-2 adrenergic receptor agonist” CHEMBL49080 ↗1“β2 agonist clenbuterol” NCT00585546 ↗ |
| Modality | Small molecule | — CHEMBL49080 ↗ |
| Route | Oral | “clenbuterol liquid 59 mcg/ml PO TID” NCT00585546 ↗ |
| Target | ADRB2 | “Beta-2 adrenergic receptor agonist” CHEMBL49080 ↗ |
| Target | DUX4 | “identified as suppressing DUX4 expression in cultured FSHD muscle” NCT06721299 ↗ |